Emily Kopp, Web Producer at Kaiser Health News, most recently worked as a freelance reporter. She has previously worked at Politico and AIS Health. Before that, she interned with the Center for Responsive Politics.
Emily Kopp
From this contributor
Nonprofit with ties to pharma launches campaign against drug imports
Both the Pharmaceutical Research and Manufacturers of America and the nonprofit group have gone to great lengths to show that drugmakers are not driving what they describe as a “grass-roots” effort to fight imports.
Nonprofit with ties to pharma launches campaign against drug imports
By
Emily Kopp, Rachel Bluth, Kaiser Health News
20 April 2017 | 8 min read
Senators want answers about reported probe of U.S. health secretary
Nine U.S. senators are pushing the U.S. Attorney General to reveal what he knows about a reported investigation into Tom Price’s stock trades that a top federal prosecutor might have begun before being fired by the Trump administration.
Senators want answers about reported probe of U.S. health secretary
By
Emily Kopp, Rachel Bluth, Kaiser Health News
31 March 2017 | 4 min read
Most patient advocacy groups accept funding from pharma
At least 83 percent of the United States' largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.
Most patient advocacy groups accept funding from pharma
By
Emily Kopp, Kaiser Health News
2 March 2017 | 5 min read
Explore more from The Transmitter
Frameshift: Shari Wiseman reflects on her pivot from science to publishing
As chief editor of Nature Neuroscience, Wiseman applies critical-thinking skills she learned in the lab to manage the journal’s day-to-day operations.
Frameshift: Shari Wiseman reflects on her pivot from science to publishing
As chief editor of Nature Neuroscience, Wiseman applies critical-thinking skills she learned in the lab to manage the journal’s day-to-day operations.
By
Katie Moisse
15 December 2025 | 7 min read
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
By
Alex Kwan
15 December 2025 | 6 min read
Dispute erupts over universal cortical brain-wave claim
The debate highlights opposing views on how the cortex transmits information.
Dispute erupts over universal cortical brain-wave claim
The debate highlights opposing views on how the cortex transmits information.
By
Claudia López Lloreda
12 December 2025 | 5 min read